Renal cell carcinoma

[1]  M. Timsit,et al.  [Renal tumors]. , 2011, La Revue du praticien.

[2]  E. Small,et al.  Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Halushka,et al.  Heart failure associated with sunitinib malate , 2008, Cancer.

[4]  M. Gore.  Interferon-α (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): Results of the randomised MRC/EORTC RE04 trial , 2008 .

[5]  R. Figlin,et al.  Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .

[6]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[7]  J. Kaouk,et al.  Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. , 2008, The Journal of urology.

[8]  R. Uzzo,et al.  Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. , 2008, The Journal of urology.

[9]  J. Kaouk,et al.  Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney. , 2008, The Journal of urology.

[10]  B. Rini,et al.  Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin , 2008, Clinical Cancer Research.

[11]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[12]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[13]  M. Zhou,et al.  Renal mass biopsy--a renaissance? , 2008, The Journal of urology.

[14]  Christine O Menias,et al.  Benign renal neoplasms in adults: cross-sectional imaging findings. , 2008, AJR. American journal of roentgenology.

[15]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[16]  A. Ravaud,et al.  Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis , 2007, Cancer.

[17]  P. A. van den Brandt,et al.  Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies , 2007, International journal of cancer.

[18]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Louis R Kavoussi,et al.  Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. , 2007, The Journal of urology.

[20]  J. Elting,et al.  Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis , 2007 .

[21]  R. Bukowski,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results , 2007 .

[22]  B. Rini,et al.  The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.

[23]  R. Abraham,et al.  The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy , 2007, Clinical Cancer Research.

[24]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  V. Margulis,et al.  Renal cell carcinoma clinically involving adjacent organs , 2007, Cancer.

[26]  Jihad H Kaouk,et al.  Ablative techniques for the management of kidney cancer , 2007, Nature Clinical Practice Urology.

[27]  B. Hollenbeck,et al.  Five‐year survival after surgical treatment for kidney cancer , 2007, Cancer.

[28]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[29]  B. Rini,et al.  Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. , 2007, Journal of the National Cancer Institute.

[30]  E. Halpern,et al.  Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. , 2006, Kidney international.

[31]  M. Blute.  Sunitinib in patients with metastatic renal cell carcinoma , 2006 .

[32]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[33]  Stephanie Daignault,et al.  Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect , 2006 .

[34]  E. Small,et al.  A phase II study of gemcitabine and capecitabine in metastatic renal cancer , 2006, Cancer.

[35]  H. Klingler,et al.  Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. , 2006, The Journal of urology.

[36]  Andrew J Vickers,et al.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. , 2006, The Lancet. Oncology.

[37]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[38]  John T. Wei,et al.  National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? , 2006, Urology.

[39]  A. Hanlon,et al.  The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. , 2006, The Journal of urology.

[40]  M. Gordon.  Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma , 2006 .

[41]  B. Konety.  Renal cryoablation: Outcome at 3 years , 2006 .

[42]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[44]  P. Chaves,et al.  Kidney function as a predictor of noncardiovascular mortality. , 2005, Journal of the American Society of Nephrology : JASN.

[45]  R. Goldbohm,et al.  Vegetable and fruit consumption and risk of renal cell carcinoma: Results from the Netherlands cohort study , 2005, International journal of cancer.

[46]  R. Parker,et al.  Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy , 2005, Journal of immunotherapy.

[47]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[48]  P. Brennan,et al.  Renal cell carcinoma in relation to cigarette smoking: Meta‐analysis of 24 studies , 2005, International journal of cancer.

[49]  P. Fornara,et al.  Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) , 2005, British Journal of Cancer.

[50]  E. Blackstone,et al.  Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? , 2005, The Annals of thoracic surgery.

[51]  E. Small,et al.  A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma , 2005, Cancer.

[52]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Wolk,et al.  Fruits, vegetables and risk of renal cell carcinoma: A prospective study of Swedish women , 2005, International journal of cancer.

[54]  M. Atkins,et al.  Systemic therapy for renal cell carcinoma. , 2005, Cancer chemotherapy and biological response modifiers.

[55]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[56]  T. Bjørge,et al.  Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. , 2004, American journal of epidemiology.

[57]  R. Goldbohm,et al.  Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. , 2004, American journal of epidemiology.

[58]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[59]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[60]  J. Cheville,et al.  The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus , 2004, BJU international.

[61]  S. Loening,et al.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Cheville,et al.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. , 2004, The Journal of urology.

[63]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  A. Billis.  Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. , 2004, International braz j urol : official journal of the Brazilian Society of Urology.

[65]  W Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2006 .

[66]  J. Cheville,et al.  Solid renal tumors: an analysis of pathological features related to tumor size. , 2003, The Journal of urology.

[67]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[68]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Figlin,et al.  Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[71]  J. Manola,et al.  Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[73]  R. Honda,et al.  Twenty-year follow-up of acquired renal cystic disease. , 2003, Clinical nephrology.

[74]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  H. Dienemann,et al.  Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. , 2002, The Annals of thoracic surgery.

[77]  A. Kuten,et al.  Postoperative Irradiation in Localized Renal Cell Carcinoma: The Rambam Medical Center Experience , 2002, Tumori.

[78]  A. Renshaw.  Subclassification of renal cell neoplasms: an update for the practising pathologist. , 2002, Histopathology.

[79]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  A. Belldegrun,et al.  Changing concepts in the management of renal oncocytoma. , 2002, Urology.

[81]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[82]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[83]  M. Gramatzki,et al.  IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial , 2001, British Journal of Cancer.

[84]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[85]  A. Novick,et al.  Nephron sparing surgery for renal tumors: indications, techniques and outcomes. , 2001, The Journal of urology.

[86]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[87]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  R. Klausner,et al.  Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[89]  P. Boracchi,et al.  Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  R. Chen,et al.  Laparoscopic renal cryoablation in 32 patients. , 2000, Urology.

[91]  B. Rini,et al.  Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  R. Fisher,et al.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. , 2000, The cancer journal from Scientific American.

[93]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[94]  W. Linehan,et al.  Histopathology and molecular genetics of renal tumors toward unification of a classification system. , 1999, The Journal of urology.

[95]  T. Tammela,et al.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  J. Rossi,et al.  Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[99]  P L Choyke,et al.  Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. , 1999, The Journal of urology.

[100]  C. Junien,et al.  Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC , 1999, Human mutation.

[101]  Mimi C. Yu,et al.  Tobacco use in relation to renal cell carcinoma. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[102]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[103]  S. Clifford,et al.  Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. , 1998, Genes, chromosomes & cancer.

[104]  R. Makarewicz,et al.  The value of postoperative radiotherapy in advanced renal cell cancer. , 1998, Neoplasma.

[105]  A. Ravaud,et al.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.

[106]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[107]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[108]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[109]  R. Fisher,et al.  Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  R. Talamini,et al.  Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette‐Guèrin: Five‐year results of a prospective randomized study , 1996, Cancer.

[111]  M. Blute,et al.  Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. , 1996, The Journal of urology.

[112]  H. Adami,et al.  International renal‐cell cancer study. VIII. Role of diuretics, other anti‐hypertensive medications and hypertension , 1995, International journal of cancer.

[113]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  D. Petrylak,et al.  Chemotherapy for advanced renal-cell carcinoma: 1983-1993. , 1995, Seminars in oncology.

[115]  J. Mclaughlin,et al.  International renal‐cell cancer study. II. Analgesics , 1995, International journal of cancer.

[116]  F. Mostofi,et al.  Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy , 1995, The American journal of surgical pathology.

[117]  A. Novick,et al.  Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. , 1995, Urology.

[118]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[119]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[120]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[121]  E. Lopez Hänninen,et al.  Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. , 1993, European journal of cancer.

[122]  K. Vermeylen,et al.  Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. , 1992, European journal of cancer.

[123]  L. Einhorn,et al.  Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  D. Faller,et al.  Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. , 1990, The Journal of clinical investigation.

[125]  L. Piva,et al.  Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. , 1987, The Journal of urology.

[126]  M. Kjaer,et al.  Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. , 1987, International journal of radiation oncology, biology, physics.

[127]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[128]  L. Piva,et al.  Hormone Treatment and Sex Steroid Receptors in Metastatic Renal Cell Carcinoma: Report of a Multicentric Prospective Study , 1983, Tumori.

[129]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.

[130]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[131]  A. Levy,et al.  Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy , 1977, The American journal of the medical sciences.

[132]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.

[133]  G. Farrow,et al.  Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. I. , 1968, Cancer.

[134]  G. Farrow,et al.  Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3. , 1968, Cancer.

[135]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.